IN THE CLAIMS:

- 1. (original) An antibody which binds selectively to carbohydrate deficient transferrin (CDT) in aqueous solution without the latter needing to be bound to a solid phase.
- 2. (original) The antibody as claimed in claim 1, which does not bind or which binds insubstantially to the peptides P1 or P2 prepared according to EP-0 605 627.
- 3. (original) The antibody as claimed in claim 2, whose binding behavior has been established in relation either to solid phase-bound peptides P1 or P2 or peptides P1 or P2 present in aqueous solution.
- 4. (currently amended) An antibody which binds selectively to CDT, wherein the binding takes place in the region of the following segments (1) to (4) of the CDT sequence:

SEQ ID NO: (1)	VVARSMGGKEDLIWELL	and
SEQ ID NO: (2)	TTEDSIAKIMNGEADAMSLDGGF	and
SEQ ID NO: (3)	SKLSMGSGLNLSEPN	and
SEQ ID NO: (4)	YEKYLGEEYVKAV.	

- 5. (original) The antibody as claimed in claim 4, wherein the binding takes place only in the region of three of the segments (1) to (4) of the sequence.
- 6. (original) The antibody as claimed in claim 4, wherein the binding takes place only in the region of two of the segments (1) to (4) of the sequence.
- 7. (currently amended) The antibody as claimed in any of claims claim 1 to 6, which is a monoclonal antibody.
- 8. (original) A monoclonal antibody which is produced by the cell culture having the deposition number DSM ACC2540.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

- 9. (original) A monoclonal antibody which is produced by the cell culture having the deposition number DSM ACC2541.
- 10. (currently amended) An antigen-binding fragment which can be prepared from an antibody as claimed in claim 1 any of the preceding claims 1 to 9.
- 11. (original) A process for preparing the antibody as claimed in claim 1 by immunizing a suitable experimental animal with unglycosylated transferrin, fusing the spleen cells of this experimental animal to myeloma cells, resulting in antibody-producing hybrid cells, cloning the hybrid cells and selecting a hybrid cell clone which produces an antibody which selectively binds to CDT in aqueous solution without the latter needing to be bound to a solid phase, and obtaining antibodies by a process known to the skilled worker from the hybrid cell clone selected in this way.
- 12. (currently amended) A process for preparing the antibody as claimed in claim 4 by immunizing a suitable experimental animal with unglycosylated transferrin, fusing the spleen cells of this experimental animal to myeloma cells, resulting in antibody-producing hybrid cells, cloning the hybrid cells and selecting a hybrid cell clone which produces an antibody whose binding according to the results of an epitope mapping takes place in the region of the following segments (1) to (4) of the CDT sequence:

SEQ ID NO: (1)	VVARSMGGKEDLIWELL	and
----------------	-------------------	-----

and obtaining antibodies by a process known to the skilled worker from the hybrid cell clone selected in this way.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

- 13. (currently amended) An immunoassay for detecting CDT in a sample, which comprises bringing an antibody as claimed in <u>claim 1</u> any of claims 1 to 9 or the antigen binding fragment as claimed in claim 10 into contact with the sample, and determining qualitatively or quantitatively the formation of an immune complex involving CDT.
- 14. (currently amended) A test kit for carrying out an immunoassay as claimed in claim 13 comprising an antibody as claimed in any of claims 1 to 9 or the antigen-binding fragment as claimed in claim 10.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com